Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for ...
– Developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions – – Lead clinical program, KAI-9531, an injectable GLP-1/GIP receptor dual agonist, …